Childhood maltreatment and cognitive functioning in patients with major depressive disorder: A CAN-BIND-1 report

Trisha Chakrabarty; Kate L. Harkness; Shane J. McInerney; Lena C. Quilty; Roumen V. Milev; Sidney H. Kennedy; Benicio N. Frey; Glenda M. MacQueen; Daniel J. Müller; Susan Rotzinger; Rudolf Uher; Raymond W. Lam

doi:10.1017/S003329171900268X

Childhood maltreatment and cognitive functioning in patients with major depressive disorder: A CAN-BIND-1 report

Trisha Chakrabarty, Kate L. Harkness, Shane J. McInerney, Lena C. Quilty, Roumen V. Milev, Sidney H. Kennedy, Benicio N. Frey, Glenda M. MacQueen, Daniel J. Müller, Susan Rotzinger, Rudolf Uher, Raymond W. Lam

Medicine

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

20 Citas (Scopus)

Resumen

Background Patients with major depressive disorder (MDD) display cognitive deficits in acutely depressed and remitted states. Childhood maltreatment is associated with cognitive dysfunction in adults, but its impact on cognition and treatment related cognitive outcomes in adult MDD has received little consideration. We investigate whether, compared to patients without maltreatment and healthy participants, adult MDD patients with childhood maltreatment display greater cognitive deficits in acute depression, lower treatment-Associated cognitive improvements, and lower cognitive performance in remission. Methods Healthy and acutely depressed MDD participants were enrolled in a multi-center MDD predictive marker discovery trial. MDD participants received 16 weeks of standardized antidepressant treatment. Maltreatment and cognition were assessed with the Childhood Experience of Care and Abuse interview and the CNS Vital Signs battery, respectively. Cognitive scores and change from baseline to week 16 were compared amongst MDD participants with (DM+, n = 93) and without maltreatment (DM-, n = 90), and healthy participants with (HM+, n = 22) and without maltreatment (HM-, n = 80). Separate analyses in MDD participants who remitted were conducted. Results DM+ had lower baseline global cognition, processing speed, and memory v. HM-, with no significant baseline differences amongst DM-, HM+, and HM-groups. There were no significant between-group differences in cognitive change over 16 weeks. Post-Treatment remitted DM+, but not remitted DM-, scored significantly lower than HM-in working memory and processing speed. Conclusions Childhood maltreatment was associated with cognitive deficits in depressed and remitted adults with MDD. Maltreatment may be a risk factor for more severe and persistent cognitive deficits in adult MDD.

Idioma original	English
Páginas (desde-hasta)	2536-2547
Número de páginas	12
Publicación	Psychological Medicine
Volumen	50
N.º	15
DOI	https://doi.org/10.1017/S003329171900268X
Estado	Published - nov. 2020

Nota bibliográfica

Funding Information:
Financial support. CAN-BIND is an Integrated Discovery Program carried out in partnership with, and financial support from, the Ontario Brain Institute (grant title ‘Canadian Biomarker Integration Network for Depression (CAN-BIND)’), an independent non-profit corporation, funded partially by the Ontario government. The opinions, results and conclusions are those of the authors and no endorsement by the Ontario Brain Institute is intended or should be inferred. Additional funding was provided by CIHR, Lundbeck, Bristol-Myers Squibb, Pfizer, and Servier. Funding and/or in kind support is also provided by the investigators’ universities and academic institutions. All study medications are independently purchased at wholesale market values.

Funding Information:
Conflict of interest. Dr Chakrabarty, Dr Harkness, Dr Quilty and Dr Uher report no competing interests. Dr McInerney has received advisory panel income from Janssen and research grant funding through the Healthy Minds Canada/Pfizer Canada Workplace Depression Awards. Dr Milev has received honoraria for ad hoc speaking or advising/consulting, or received research funds, from: Lundbeck, Pfizer, Shire, Sunovion, Janssen, Allergan, BMS, Otsuka, Merck, Canadian Institutes of Health Research, Canadian Biomarker Integration Network for Depression, Ontario Brain Institute, and Ontario Mental Health Foundation. Dr Kennedy has received research funding or honoraria from the following sources: Abbott, Alkermes, Allergan, BMS, Brain Canada, Canadian Institutes for Health Research, Janssen, Lundbeck, Lundbeck Institute, Ontario Brain Institute, Ontario Research Fund, Otsuka, Pfizer, Servier, Sunovion and Xian-Janssen. Dr Frey has served on advisory board for Otsuka and received research grants from Pfizer. Dr MacQueen has received honoraria for ad hoc speaking or advising/consulting, or received research funds, from: Ontario Brain Institute, Canadian Institutes of Health Research, Pfizer, Lundbeck, Janssen, Johnson & Johnson, Allergan. Dr Müller has received research funds from the Centre for Addiction and Mental Health Foundation, Canadian Institutes of Health Research, and the National Institute of Health. Dr Rotzinger holds a patent ‘Teneurin C-Terminal Associated Peptides (TCAP) and methods and uses thereof. Inventors: David Lovejoy, R.B. Chewpoy, Dalia Barsyte, Susan Rotzinger.’ Dr Lam has received honoraria for ad hoc speaking or advising/consulting, or received research funds, from: Akili, Allergan, Asia-Pacific Economic Cooperation, BC Leading Edge Foundation, Brain Canada, Canadian Institutes of Health Research, Canadian Network for Mood and Anxiety Treatments, Canadian Psychiatric Association, CME Institute, Hansoh, Janssen, Lundbeck, Lundbeck Institute, Medscape, Mind Mental Health Technologies, Otsuka, Pfizer, St. Jude Medical, University Health Network Foundation, and Vancouver General Hospital Foundation.

Publisher Copyright:
Copyright © Cambridge University Press 2019.

ASJC Scopus Subject Areas

Applied Psychology
Psychiatry and Mental health

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1017/S003329171900268X

Otros archivos y enlaces

Citar esto

Chakrabarty, T., Harkness, K. L., McInerney, S. J., Quilty, L. C., Milev, R. V., Kennedy, S. H., Frey, B. N., MacQueen, G. M., Müller, D. J., Rotzinger, S., Uher, R., & Lam, R. W. (2020). Childhood maltreatment and cognitive functioning in patients with major depressive disorder: A CAN-BIND-1 report. Psychological Medicine, 50(15), 2536-2547. https://doi.org/10.1017/S003329171900268X

Chakrabarty, T, Harkness, KL, McInerney, SJ, Quilty, LC, Milev, RV, Kennedy, SH, Frey, BN, MacQueen, GM, Müller, DJ, Rotzinger, S, Uher, R & Lam, RW 2020, 'Childhood maltreatment and cognitive functioning in patients with major depressive disorder: A CAN-BIND-1 report', Psychological Medicine, vol. 50, n.º 15, pp. 2536-2547. https://doi.org/10.1017/S003329171900268X

@article{66790c17c6c94ab489c8656b1f75b469,

title = "Childhood maltreatment and cognitive functioning in patients with major depressive disorder: A CAN-BIND-1 report",

abstract = "Background Patients with major depressive disorder (MDD) display cognitive deficits in acutely depressed and remitted states. Childhood maltreatment is associated with cognitive dysfunction in adults, but its impact on cognition and treatment related cognitive outcomes in adult MDD has received little consideration. We investigate whether, compared to patients without maltreatment and healthy participants, adult MDD patients with childhood maltreatment display greater cognitive deficits in acute depression, lower treatment-Associated cognitive improvements, and lower cognitive performance in remission. Methods Healthy and acutely depressed MDD participants were enrolled in a multi-center MDD predictive marker discovery trial. MDD participants received 16 weeks of standardized antidepressant treatment. Maltreatment and cognition were assessed with the Childhood Experience of Care and Abuse interview and the CNS Vital Signs battery, respectively. Cognitive scores and change from baseline to week 16 were compared amongst MDD participants with (DM+, n = 93) and without maltreatment (DM-, n = 90), and healthy participants with (HM+, n = 22) and without maltreatment (HM-, n = 80). Separate analyses in MDD participants who remitted were conducted. Results DM+ had lower baseline global cognition, processing speed, and memory v. HM-, with no significant baseline differences amongst DM-, HM+, and HM-groups. There were no significant between-group differences in cognitive change over 16 weeks. Post-Treatment remitted DM+, but not remitted DM-, scored significantly lower than HM-in working memory and processing speed. Conclusions Childhood maltreatment was associated with cognitive deficits in depressed and remitted adults with MDD. Maltreatment may be a risk factor for more severe and persistent cognitive deficits in adult MDD. ",

author = "Trisha Chakrabarty and Harkness, {Kate L.} and McInerney, {Shane J.} and Quilty, {Lena C.} and Milev, {Roumen V.} and Kennedy, {Sidney H.} and Frey, {Benicio N.} and MacQueen, {Glenda M.} and M{\"u}ller, {Daniel J.} and Susan Rotzinger and Rudolf Uher and Lam, {Raymond W.}",

note = "Funding Information: Financial support. CAN-BIND is an Integrated Discovery Program carried out in partnership with, and financial support from, the Ontario Brain Institute (grant title {\textquoteleft}Canadian Biomarker Integration Network for Depression (CAN-BIND){\textquoteright}), an independent non-profit corporation, funded partially by the Ontario government. The opinions, results and conclusions are those of the authors and no endorsement by the Ontario Brain Institute is intended or should be inferred. Additional funding was provided by CIHR, Lundbeck, Bristol-Myers Squibb, Pfizer, and Servier. Funding and/or in kind support is also provided by the investigators{\textquoteright} universities and academic institutions. All study medications are independently purchased at wholesale market values. Funding Information: Conflict of interest. Dr Chakrabarty, Dr Harkness, Dr Quilty and Dr Uher report no competing interests. Dr McInerney has received advisory panel income from Janssen and research grant funding through the Healthy Minds Canada/Pfizer Canada Workplace Depression Awards. Dr Milev has received honoraria for ad hoc speaking or advising/consulting, or received research funds, from: Lundbeck, Pfizer, Shire, Sunovion, Janssen, Allergan, BMS, Otsuka, Merck, Canadian Institutes of Health Research, Canadian Biomarker Integration Network for Depression, Ontario Brain Institute, and Ontario Mental Health Foundation. Dr Kennedy has received research funding or honoraria from the following sources: Abbott, Alkermes, Allergan, BMS, Brain Canada, Canadian Institutes for Health Research, Janssen, Lundbeck, Lundbeck Institute, Ontario Brain Institute, Ontario Research Fund, Otsuka, Pfizer, Servier, Sunovion and Xian-Janssen. Dr Frey has served on advisory board for Otsuka and received research grants from Pfizer. Dr MacQueen has received honoraria for ad hoc speaking or advising/consulting, or received research funds, from: Ontario Brain Institute, Canadian Institutes of Health Research, Pfizer, Lundbeck, Janssen, Johnson & Johnson, Allergan. Dr M{\"u}ller has received research funds from the Centre for Addiction and Mental Health Foundation, Canadian Institutes of Health Research, and the National Institute of Health. Dr Rotzinger holds a patent {\textquoteleft}Teneurin C-Terminal Associated Peptides (TCAP) and methods and uses thereof. Inventors: David Lovejoy, R.B. Chewpoy, Dalia Barsyte, Susan Rotzinger.{\textquoteright} Dr Lam has received honoraria for ad hoc speaking or advising/consulting, or received research funds, from: Akili, Allergan, Asia-Pacific Economic Cooperation, BC Leading Edge Foundation, Brain Canada, Canadian Institutes of Health Research, Canadian Network for Mood and Anxiety Treatments, Canadian Psychiatric Association, CME Institute, Hansoh, Janssen, Lundbeck, Lundbeck Institute, Medscape, Mind Mental Health Technologies, Otsuka, Pfizer, St. Jude Medical, University Health Network Foundation, and Vancouver General Hospital Foundation. Publisher Copyright: Copyright {\textcopyright} Cambridge University Press 2019.",

year = "2020",

month = nov,

doi = "10.1017/S003329171900268X",

language = "English",

volume = "50",

pages = "2536--2547",

journal = "Psychological Medicine",

issn = "0033-2917",

publisher = "Cambridge University Press",

number = "15",

}

TY - JOUR

T1 - Childhood maltreatment and cognitive functioning in patients with major depressive disorder

T2 - A CAN-BIND-1 report

AU - Chakrabarty, Trisha

AU - Harkness, Kate L.

AU - McInerney, Shane J.

AU - Quilty, Lena C.

AU - Milev, Roumen V.

AU - Kennedy, Sidney H.

AU - Frey, Benicio N.

AU - MacQueen, Glenda M.

AU - Müller, Daniel J.

AU - Rotzinger, Susan

AU - Uher, Rudolf

AU - Lam, Raymond W.

N1 - Funding Information: Financial support. CAN-BIND is an Integrated Discovery Program carried out in partnership with, and financial support from, the Ontario Brain Institute (grant title ‘Canadian Biomarker Integration Network for Depression (CAN-BIND)’), an independent non-profit corporation, funded partially by the Ontario government. The opinions, results and conclusions are those of the authors and no endorsement by the Ontario Brain Institute is intended or should be inferred. Additional funding was provided by CIHR, Lundbeck, Bristol-Myers Squibb, Pfizer, and Servier. Funding and/or in kind support is also provided by the investigators’ universities and academic institutions. All study medications are independently purchased at wholesale market values. Funding Information: Conflict of interest. Dr Chakrabarty, Dr Harkness, Dr Quilty and Dr Uher report no competing interests. Dr McInerney has received advisory panel income from Janssen and research grant funding through the Healthy Minds Canada/Pfizer Canada Workplace Depression Awards. Dr Milev has received honoraria for ad hoc speaking or advising/consulting, or received research funds, from: Lundbeck, Pfizer, Shire, Sunovion, Janssen, Allergan, BMS, Otsuka, Merck, Canadian Institutes of Health Research, Canadian Biomarker Integration Network for Depression, Ontario Brain Institute, and Ontario Mental Health Foundation. Dr Kennedy has received research funding or honoraria from the following sources: Abbott, Alkermes, Allergan, BMS, Brain Canada, Canadian Institutes for Health Research, Janssen, Lundbeck, Lundbeck Institute, Ontario Brain Institute, Ontario Research Fund, Otsuka, Pfizer, Servier, Sunovion and Xian-Janssen. Dr Frey has served on advisory board for Otsuka and received research grants from Pfizer. Dr MacQueen has received honoraria for ad hoc speaking or advising/consulting, or received research funds, from: Ontario Brain Institute, Canadian Institutes of Health Research, Pfizer, Lundbeck, Janssen, Johnson & Johnson, Allergan. Dr Müller has received research funds from the Centre for Addiction and Mental Health Foundation, Canadian Institutes of Health Research, and the National Institute of Health. Dr Rotzinger holds a patent ‘Teneurin C-Terminal Associated Peptides (TCAP) and methods and uses thereof. Inventors: David Lovejoy, R.B. Chewpoy, Dalia Barsyte, Susan Rotzinger.’ Dr Lam has received honoraria for ad hoc speaking or advising/consulting, or received research funds, from: Akili, Allergan, Asia-Pacific Economic Cooperation, BC Leading Edge Foundation, Brain Canada, Canadian Institutes of Health Research, Canadian Network for Mood and Anxiety Treatments, Canadian Psychiatric Association, CME Institute, Hansoh, Janssen, Lundbeck, Lundbeck Institute, Medscape, Mind Mental Health Technologies, Otsuka, Pfizer, St. Jude Medical, University Health Network Foundation, and Vancouver General Hospital Foundation. Publisher Copyright: Copyright © Cambridge University Press 2019.

PY - 2020/11

Y1 - 2020/11

N2 - Background Patients with major depressive disorder (MDD) display cognitive deficits in acutely depressed and remitted states. Childhood maltreatment is associated with cognitive dysfunction in adults, but its impact on cognition and treatment related cognitive outcomes in adult MDD has received little consideration. We investigate whether, compared to patients without maltreatment and healthy participants, adult MDD patients with childhood maltreatment display greater cognitive deficits in acute depression, lower treatment-Associated cognitive improvements, and lower cognitive performance in remission. Methods Healthy and acutely depressed MDD participants were enrolled in a multi-center MDD predictive marker discovery trial. MDD participants received 16 weeks of standardized antidepressant treatment. Maltreatment and cognition were assessed with the Childhood Experience of Care and Abuse interview and the CNS Vital Signs battery, respectively. Cognitive scores and change from baseline to week 16 were compared amongst MDD participants with (DM+, n = 93) and without maltreatment (DM-, n = 90), and healthy participants with (HM+, n = 22) and without maltreatment (HM-, n = 80). Separate analyses in MDD participants who remitted were conducted. Results DM+ had lower baseline global cognition, processing speed, and memory v. HM-, with no significant baseline differences amongst DM-, HM+, and HM-groups. There were no significant between-group differences in cognitive change over 16 weeks. Post-Treatment remitted DM+, but not remitted DM-, scored significantly lower than HM-in working memory and processing speed. Conclusions Childhood maltreatment was associated with cognitive deficits in depressed and remitted adults with MDD. Maltreatment may be a risk factor for more severe and persistent cognitive deficits in adult MDD.

AB - Background Patients with major depressive disorder (MDD) display cognitive deficits in acutely depressed and remitted states. Childhood maltreatment is associated with cognitive dysfunction in adults, but its impact on cognition and treatment related cognitive outcomes in adult MDD has received little consideration. We investigate whether, compared to patients without maltreatment and healthy participants, adult MDD patients with childhood maltreatment display greater cognitive deficits in acute depression, lower treatment-Associated cognitive improvements, and lower cognitive performance in remission. Methods Healthy and acutely depressed MDD participants were enrolled in a multi-center MDD predictive marker discovery trial. MDD participants received 16 weeks of standardized antidepressant treatment. Maltreatment and cognition were assessed with the Childhood Experience of Care and Abuse interview and the CNS Vital Signs battery, respectively. Cognitive scores and change from baseline to week 16 were compared amongst MDD participants with (DM+, n = 93) and without maltreatment (DM-, n = 90), and healthy participants with (HM+, n = 22) and without maltreatment (HM-, n = 80). Separate analyses in MDD participants who remitted were conducted. Results DM+ had lower baseline global cognition, processing speed, and memory v. HM-, with no significant baseline differences amongst DM-, HM+, and HM-groups. There were no significant between-group differences in cognitive change over 16 weeks. Post-Treatment remitted DM+, but not remitted DM-, scored significantly lower than HM-in working memory and processing speed. Conclusions Childhood maltreatment was associated with cognitive deficits in depressed and remitted adults with MDD. Maltreatment may be a risk factor for more severe and persistent cognitive deficits in adult MDD.

UR - http://www.scopus.com/inward/record.url?scp=85073020824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073020824&partnerID=8YFLogxK

U2 - 10.1017/S003329171900268X

DO - 10.1017/S003329171900268X

M3 - Article

C2 - 31583989

AN - SCOPUS:85073020824

SN - 0033-2917

VL - 50

SP - 2536

EP - 2547

JO - Psychological Medicine

JF - Psychological Medicine

IS - 15

ER -

Childhood maltreatment and cognitive functioning in patients with major depressive disorder: A CAN-BIND-1 report

Resumen

Nota bibliográfica

ASJC Scopus Subject Areas

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto